Nuvectis Pharma (NVCT) IPO: How to buy the stock?

November 29, 2021 07:53 AM PST | By Rupam Roy
Follow us on Google News:


  • Nuvectis is expected to offer 2.3 million shares of its common stocks to investors.

  • The expected price range of the offering is US$12 to US$14 per share.

  • The firm is likely to debut in the US stock market next month.

Biotechnology firm Nuvectis Pharma Inc. is all set to debut in the US stock market next month.

The company hopes to raise about US$30 million from the IPO, according to its S-1/A registration statement filed on Oct 6 with the US Securities and Exchange Commission (SEC).

What does Nuvectis Pharma, Inc. do?

Nuvectis Pharma is a preclinical-stage biopharmaceutical company and develops treatments for various malignant tumors, including ovarian cancer and oncology-related problems. The Fort Lee, New Jersey-based company, led by its co-founder Ron Bentsur, was founded in 2020.

Bentsur, who previously served as the CEO of UroGen Pharma and Keryx Biopharmaceuticals, is the current chairman, CEO, and president of Nuvectis Pharma.

Nuvectis Pharma has two novel drug candidates: NXP800 and NXP900.

The NXP800 is an oral small molecule HSF1-pathway inhibitor, and the NXP900 is an oral small-molecule SRC/YES1 kinase inhibitor.

On Sep 14, 2021, Nuvectis Pharma has announced receiving exclusive worldwide rights for developing and commercializing novel, oral, small molecule, SRC/YES1 inhibitor from Scotland's University of Edinburgh. The compound name of the SRC/YES1 inhibitor is NXP900.

The compound was developed by the University of Edinburgh’s Institute of Genetics and Cancer. It is expected to start its IND-enabling studies in Q4, FY21, it said in a release.

Also Read: Five high-growth tech stocks to watch in 2022

Nuvectis Pharma is expected to start trading on Nasdaq under the ticker “NVCT” on December 1

Also Read: Civic coin (CVC) gives over 555% return YTD, but is it worth the bet?

Share offerings and pricing:

The New Jersey-based firm is expected to offer 2.3 million shares of its common stocks for investors. In addition, it is expected to offer 345,000 shares of its common stocks for the underwriters. Its pre-IPO common shares outstanding is over 9.51 million, according to its filing.

The expected IPO price range is US$12 to US$14 per share. It is expected to debut in the Nasdaq Global Market (NASDAQ) under the ticker symbol "NVCT" on December 1.

Also Read: THORChain (RUNE) crypto price projection after 737% YTD bull run

Company financials:

In the nine months ended on September 30, 2021, it reported a net loss of US$10.62 million.
The company's cash and cash equivalents were US$6.80 million as of Sep 30, 2021.

Also Read: Guess why Moderna (MRNA) stock jumped 23% Friday?


The year 2021 has been a year of IPOs for the US stock market, with a record 991 public offerings. As of November 29, 2021, the US IPOs were up 145.3% compared to 404 in the same period a year ago. Observers expect the Nuvectis Pharma IPO to attract more institutional investors that are looking for long term hold.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Top Listed Companies